Solid Biosciences Inc. (SLDB) earnings date
Feb 23, 2027, before open estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 10% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-19
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 46 days, typically, give or take 33 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q4 FY2025 | Fri, Mar 6, 2026 | after close | 65 | 8-K |
| Q3 FY2025 | Mon, Nov 3, 2025 | after close | 34 | 8-K |
| Q4 FY2024 | Tue, Feb 18, 2025 | before open | 49 | 8-K |
| Q3 FY2023 | Mon, Jan 8, 2024 | before open | 100 | 8-K |
| Q3 FY2022 | Mon, Jan 9, 2023 | before open | 101 | 8-K |
| Q2 FY2022 | Thu, Aug 11, 2022 | before open | 42 | 8-K |
| Q1 FY2022 | Wed, Apr 27, 2022 | before open | 27 | 8-K |
| Q4 FY2021 | Mon, Jan 10, 2022 | before open | 10 | 8-K |
What they guided beta
| Q3 FY2025 | "Solid Biosciences Reports Third Quarter 2025 Financial Results and Provides Update on INSPIRE DUCHENNE Clinical Trial Progress and Planned Regulatory Discussions - Duchenne (SGT-003): 23 participants have been dosed in the INSPIRE DUCHENNE trial as of October 31, 2025; Solid expects to have dosed 30 participants in total by early 2026, then plans to meet with the FDA to discuss potential registrational pathways in H1 2026 - - SGT-003 has been generally well tolerated using a steroid-only prophylactic immunomodulation regimen; cardiac safety monitoring continued to show reduction in cardiac i" exhibit |
| Q3 FY2025 | "Later in the fourth quarter of 2025, we also expect to activate our first clinical trial site for ARTEMIS, a first-in-human Phase 1b clinical trial evaluating SGT-501, our gene therapy candidate intended to treat catecholaminergic polymorphic ventricular tachycardia." exhibit |
| Q3 FY2025 | "The Company expects to dose a total of 30 participants by early 2026." exhibit |
| Q3 FY2025 | "Critically, Solid has aligned with the FDA on SGT-003’s potency assay strategy and will continue additional commercial-readiness CMC activities, with PPQ manufacturing batches expected to be completed in 2026." exhibit |
| Q3 FY2025 | "SGT-501 for Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) In the fourth quarter of 2025, Solid expects to activate the first clinical trial site for ARTEMIS, a first-in-human, open-label, Phase 1b clinical trial of SGT-501." exhibit |
| Q4 FY2024 | ">10 participants total projected to be 50 1 N=3, MEAN 110% : dosed by early Q2 2025 0 Participant Participant Participant Mean 1 2 3" exhibit |
| Q4 FY2024 | "Approximately 20 participants total projected to be dosed by Q4 2025 Baseline Day 90 Day 90 DYSTROPHIN POSITIVE In first 3 participants dosed (Day 90), FIBERS (IF) SGT-003 showed: 1 N=3, MEAN 78% :" exhibit |
| Q4 FY2024 | "Adverse Events expected and consistent with AAV gene therapy 18 © 2025 Solid Biosciences" exhibit |
| Q4 FY2024 | "Participant enrollment continues: >10 participants in total expected to be dosed by early Q2 2025" exhibit |
| Q4 FY2024 | "Global clinical site expansion underway: additional sites expected to be activated by year-end 2025" exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/SLDB
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/SLDB
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/SLDB/"><img src="https://veritasdata.dev/embed/SLDB.svg" alt="SLDB earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/SLDB/)
Script
<script async src="https://veritasdata.dev/embed/SLDB.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/SLDB"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.